Germline SMARCB1 mutations (RTPS1) are present in 25–35% of ATRT patients, who tend to be younger with more extensive disease [43,49,50]; the penetrance of RTPS1 is high, approximately 90% by age 5 [51]. Here, SMARCB1 is linked to atypical teratoid rhabdoid tumor.